The risks associated with COVID-19 infection are higher for immunocompromised individuals and people over 65 than the general public. ImmunoCARE is an innovative research project to study whether repeated at-home tests, on-demand telemedicine, and quick delivery of medication for those who test positive for COVID-19 can reduce COVID-19 severity in immunocompromised people.
ImmunoCARE is a joint research project from Scripps Research – a renowned biomedical research organization — and Cue Health, a leading health care technology company that develops portable diagnostic tests for at-home use.
Watch co-principal investigators Eric Topol, MD and Julia Moore Vogel, PhD to learn more about our motivations and vision.
ImmunoCARE is available to individuals who are moderately to severely immunocompromised. Participants will provide documentation from a medical provider confirming their diagnosis.
Additional inclusion criteria includes:
ImmunoCARE will enroll 10,000 participants. Half of participants will test for COVID-19 and seek care as they normally would; the other half will receive at-home COVID-19 tests from Cue Health for themselves and others in their household. All participants will be asked to complete monthly surveys about COVID-19 exposure, infection, and hospitalization.
As our thanks for your participation, all eligible participants will receive a series of Amazon gift cards as compensation for time throughout the study.
Interested in helping advance research on COVID-19 outcomes for immunocompromised individuals? Click below to see if you are eligible to participate!
Questions? Reach out to us at ImmunoCARE@scripps.edu
Already joined the study? Log in at mydatahelps.org.